Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Condition(s) studied
Investigational drug(s) / intervention(s)
Baricitinib 4 MG: Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
Standard treatment: Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
Study summary
The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.
Eligibility
Primary outcome measure(s)
- Clinical improvement — up to 180 days
Glasgow Outcome Scale at 180 days after brain trauma
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tandu Hospital, Fourth Military Medical University | Xi'an | Shaanxi | Recruiting |
More Tang-Du Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06065046 on ClinicalTrials.gov ↗ ← All trials in China